On November 30, 2016 Dynavax Technologies Corporation (NASDAQ: DVAX) reported that it will present clinical data from a Phase 1/2 clinical trial evaluating its immuno-oncology product, SD-101, in patients with low-grade, B cell lymphoma (Press release, Dynavax Technologies, NOV 30, 2016, View Source [SID1234516841]). The poster presentation will be made at the 58th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting and Exposition.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Abstract Name: SD-101, a Novel Class C CpG-Oligodeoxynucleotide Toll-like Receptor 9 Agonist, Given with Low Dose Radiation for Untreated Low Grade B-Cell Lymphoma: Interim Results of a Phase 1/2 Trial
Abstract Number: 2974
Date and Time: Sunday, December 4, 2016 from 6:00 p.m. EST to 8:00 p.m. EST
Session Name: 623. Mantle Cell, Follicular and Other Indolent B-Cell Lymphoma – Clinical Studies: Poster II
Location: San Diego Convention Center, Hall GH
Note: Abstract will also be published online on December 1, 2016, in the supplemental volume of the journal Blood
About SD-101
SD-101 is Dynavax’s proprietary, second-generation, Toll-like Receptor 9 (TLR9) agonist CpG-C class oligodeoxynucleotide. SD-101 activates multiple anti-tumor activities of innate immune cells and activates plasmacytoid dendritic cells to stimulate T cells specific for antigens released from dying tumor cells. TLR9 agonists such as SD-101 enhance T and B cell responses and provide potent Type 1 interferon induction and maturation of plasmacytoid dendritic cells to antigen-presenting cells. SD-101 is being evaluated in several Phase 1/2 oncology studies to assess its safety and activity.
For information about SD-101 trials that are currently recruiting patients, please visit www.clinicaltrials.gov.